Abstract:BACKGROUND: Inflammatory cytokines like interleukin-6 (IL-6) are implicated in depression, but most studies have hitherto focused on circulating levels of IL-6 rather than its activity. IL-6 trans-signalling is thought to be responsible for most of the pathogenic effects of IL-6 and is implicated in autoimmune diseases like rheumatoid arthritis. We tested the association between a multi-protein-derived measure of IL-6 trans-signalling and clinical and cognitive outcomes in patients with depression. We hypothesised that this novel measure of IL-6 activity/bioavailability would be associated with clinical and cognitive measures previously reported to be associated with inflammation in depression.METHODS: Using data from 86 patients with International Classification of Diseases-10 diagnosis of depression, we calculated a ratio score representing IL-6 activity/bioavailability using serum IL-6, soluble IL-6 receptor (sIL-6R), and soluble glycoprotein 130 levels. We tested the relationship of this novel biomarker with 12 cytokines using correlation analyses and with cognitive and clinical measures using multivariable linear regression, following z-transformation of all immune exposures.RESULTS: The novel measure of IL-6 activity/bioavailability was correlated with IL-6 (r=0.42, P=0.03), C-reactive protein (CRP) (r=0.42, P=0.03), sIL-6R (r=0.91, P<0.01), and tumour necrosis factor alpha (r=0.43, P=0.03). The IL-6 activity/bioavailability measure was associated with higher somatic symptoms of depression (β=1.09; 95% CI 0.30, 1.88; PFDR=0.01), fatigue (β=4.34; 95% CI 1.26, 7.42; PFDR=0.03), depression severity (β=3.06; 95% CI 0.71, 5.40; P=0.02), poorer quality of life (β=-0.07; 95% CI -0.13, -0.01; PFDR=0.045), and decreased psychomotor speed (β=-5.46; 95% CI -9.09, -1.84; PFDR=0.01),. There was little evidence of associations with reaction time, anhedonia, anxiety, emotional perception and recall, executive function, and sustained attention (Ps>0.05). The effect estimates for the associations of the novel measure with depression outcomes were comparable to those for individual immune proteins (i.e., IL-6, CRP, sIL-6R).CONCLUSION: A novel multi-protein-derived measure of IL-6 activity/bioavailability shows robust associations with various inflammation-related clinical and cognitive outcomes in depression and performs well in comparison to single inflammatory proteins. We need replication of these findings in other samples, experiments for mechanistic validity of this novel biomarker, and clinical studies to assess its usefulness as a marker of illness risk and prognosis.

IL-6 and IL-8 are likely associated with psychological status in treatment naïve general population

Linking peripheral IL-6, IL-1 and hypocretin-1 with cognitive impairment from major depression

Increased Plasma Levels of IL-6 Are Associated with Striatal Structural Atrophy in Major Depressive Disorder Patients with Anhedonia

Role of inflammation in depression and anxiety: Tests for disorder specificity, linearity and potential causality of association in the UK Biobank

Ndt_a_202329 1695..1700

Ndt_a_218483 191..199

A novel biomarker of interleukin 6 activity and clinical and cognitive outcomes in depression

Elevated Interleukin-2, Interleukin-6 and Interleukin-8 Serum Levels in Neuroleptic-Free Schizophrenia: Association with Psychopathology

Associations of Depression With C-Reactive Protein, IL-1, and IL-6: A Meta-Analysis

Sex Differences in the Association of Treatment-Resistant Schizophrenia and Serum Interleukin-6 Levels

IL-8 (CXCL8) Correlations with Psychoneuroimmunological Processes and Neuropsychiatric Conditions

Association of inflammation with depression and anxiety: evidence for symptom-specificity and potential causality from UK Biobank and NESDA cohorts

Association Between Increased Serum Interleukin-8 Levels and Improved Cognition in Major Depressive Patients with SSRIs

Longitudinal Association Between Depression and Inflammatory Markers: Results From the Netherlands Study of Depression and Anxiety

High concentrations of serum interleukin-6 and interleukin-8 in patients with bipolar disorder

Relationship between serum inflammatory cytokines and suicide risk in patients with major depressive disorder

Inflammatory proteins and miRNA-144-5p in patients with depression, anxiety, or stress- and adjustment disorders after psychological treatment

Increased Serum IL-6 and IL-1 Receptor Antagonist Concentrations in Major Depression and Treatment Resistant Depression.

Stress-induced cytokine levels in patients with panic disorder and its prediction of psychotherapy outcome

Associations between IL-6 and trajectories of depressive symptoms across the life course: Evidence from ALSPAC and UK Biobank cohorts

Depression, Traumatic Stress and Interleukin-6